Latest news with #surgicalprocedures
Daily Mail
3 days ago
- Health
- Daily Mail
Plastic surgeon warns of killer complication linked to weight loss jabs
A plastic surgeon has warned that people on weight loss jabs are unknowingly putting their lives at risk when they undergo surgical procedures—and could choke to death. It's estimated that over 1.5 million people are currently taking weight loss jabs in the UK, with more soon to join them after the government gave GPs the green light to prescribe them. With them becoming a regular part of people's daily lives, a top doctor has warned of a simple mistake people might make which could prove to be deadly—forgetting to tell your doctor that you are on the jab before having a general anaesthetic. Dr Mo Akhavani, a London-based consultant plastic and cosmetic surgeon, told the Daily Mail that roughly 80 per cent of his patients are on 'some sort of jab'. He added that in his experience with his own patients, 'maybe one in ten might forget' to tell him they are taking the appetite-suppressing medication. Typically, patients are told to not eat at least six hours before a surgery to prevent a potentially deadly complication. This is aspiration pneumonia, a lung infection caused by inhaling food, liquid or saliva into the lungs, which can happen if you have food in your stomach. Dr Akhavani warned the weight loss jab 'causes problems as it delays gastric emptying'—the process of the stomach emptying contents into the small intestine. He explained it is 'very well recognised in the medical world' that you should come off the jab two weeks or a little longer before a surgery. Previously researchers in California found weight loss jabs can increase the risk of the complication, which is essentially 'choking to death', by 33 per cent. The study looked at nearly one million Americans who had an endoscopy, which examines the upper digestive tract. On their findings, the study author Dr Ali Rezaie, said: 'Aspiration during or after endoscopy can be devastating. If significant, it can lead to respiratory failure, ICU admission and even death. 'Even mild cases may require close monitoring, respiratory support and medications including antibiotics. It is important we take all possible precautions to prevent aspiration from occurring.' Dr Akhavani warned: 'If you are on these [weight loss jabs] please, please, please don't forget to let your doctors know.' In his experience, it isn't that patients are trying to hide it, but rather that they 'genuinely forget' because the jab is now a 'routine part of their life'. On weight loss jabs, he said: 'It has now become an acceptable way of managing weight. But he added: 'I have personal friends, very attractive young women, nothing wrong with them, and they are on Ozempic and they look emaciated.' However, he said: 'Others put on a lot of weight, start exercise and start to accelerate the weight loss. Those ones are probably doing it for the right reasons.' Under official guidelines, only patients who have a body mass index (BMI) of over 35 and at least one weight-related health problem like high blood pressure, or those who have a BMI of 30 to 34.9 and meet the criteria for referral to a specialist weight management service, should be prescribed weight loss jabs. The weight-loss jabs have been found to help people lose up to 20 per cent of their body weight in just a few months. However, there have been numerous reports of side effects after getting the jabs from hair loss and constipation to extreme cases of bloating. Recently, US experts found that semaglutide—the powerful ingredient behind Wegovy and Ozempic—may 'waste away muscles', making it harder to lose weight. And earlier this summer, in June, slimming jabs like Mounjaro and Wegovy were linked to more than 100 deaths in Britain. A total of 111 deaths were logged with the regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), up to and including May 29. But none of the fatalities, which have all been reported since the jabs were licensed for use in the UK, were proven to be caused directly by the drugs. However, the UK medicines regulator launched a probe into the safety of fat jabs after hundreds of Britons developed pancreatitis, specifically, leaving ten dead. Nevertheless, the weight loss jabs have remained popular, with pharmacists warning just last month that booming demand may become 'unsustainable'. The warning was issued by The National Pharmacy Association (NPA)—which represents over 6,000 community pharmacies. It came after their recent poll of over 2,000 people showed an increasing demand for private and NHS-backed weight loss services. The NDA poll revealed a fifth of participants had attempted to access weight loss treatments in the last year. This figure rose to 35 per cent for those aged between 16 and 34, compared to only seven per cent of those over 55. Earlier this week a new study revealed a daily weight loss pill that works in a similar way can help users lose an average of almost two stone (12.4kg). People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks in a groundbreaking final stage trial. The participants, who were overweight but did not have diabetes, also benefited from reductions in bad cholesterol, blood fats and blood pressure. Manufacturer Lilly said the once-a-day pill—the first of its kind—could be launched 'at scale' worldwide and 'without supply constraints' as early as next year.
Yahoo
5 days ago
- Business
- Yahoo
Zimmer Biomet raises annual profit forecast on strong demand for medical devices
(Reuters) -Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants. Medical device makers have benefited from a surge in demand as more people, particularly older Americans, sought health care services and surgical procedures. The demographic shift toward an aging population continues to fuel robust procedure volumes across orthopedic specialties. Zimmer expects 2025 adjusted profit per share in the range of $8.10 to $8.30, up from its prior view of $7.90 to $8.10 per share. Analysts were expecting $7.97 per share, according to data compiled by LSEG. "Our robust new product cycle drove significant acceleration in our U.S. hips and knees portfolios and continued strong growth in our global S.E.T. (sports medicine, extremities, and trauma) business," CEO Ivan Tornos said. The company attributed its performance to early customer adoption of its new product portfolio, including advancements in surgical robotics. Combined sales at Zimmer's hips and knees units came in at $1.36 billion during the quarter ended June 30, compared with $1.31 billion a year ago. Sales at its unit that sells sports medicine and trauma care products climbed 17.3% to $550.6 million, while analysts estimated $534 million. It posted an adjusted profit of $2.07 per share, topping estimates of $1.98 per share. Its second-quarter revenue came in at $2.08 billion, also above expectations of $2.05 billion. Zimmer said it expects 2025 revenue growth of 6.7% to 7.7%, from its prior 5.7% to 8.2% forecast.
Reuters
5 days ago
- Business
- Reuters
Becton Dickinson joins peer in raising annual profit forecast after results beat
Aug 7 (Reuters) - Becton Dickinson (BDX.N), opens new tab raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices. Shares of New Jersey-based medical device maker rose 9.8% in premarket trading. Becton manufactures and distributes medical and surgical products such as needles, syringes and disposal units. Medical devices makers have benefited from elevated demand for non-urgent surgical procedures in the U.S., especially among older adults, since the second half of 2023. The trend is expected to continue this year, after health insurers have also flagged sustained high demand for medical care. Last month, larger medical device peer Boston Scientific (BSX.N), opens new tab raised its annual profit forecast, buoyed by strong demand for its heart devices. Lab equipment maker Waters Corp (WAT.N), opens new tab last month agreed to buy a bioscience and diagnostics unit spun off from Becton in a deal valued at $17.5 billion, expanding its scale in clinical and diagnostic applications. Becton now expects its 2025 adjusted profit per share between $14.30 to $14.45, compared with its prior range of $14.06 to $14.34. It reaffirmed its annual revenue to be between $21.8 billion and $21.9 billion, compared with analysts' estimates of $21.83 billion, according to data compiled by LSEG. The company reported a profit of $3.68 per share on an adjusted basis for the quarter ended June 30, beating estimates of $3.40 per share. Quarterly sales for the company came in at $5.51 billion, above estimates of $5.49 billion. Sales from its medical unit, which makes devices to administer drugs, rose 14.4% to $2.93 billion. Analysts on average estimated $2.91 billion.
Yahoo
16-07-2025
- Business
- Yahoo
Hemostats Market worth $4.00 billion by 2030 with 6.4% CAGR
DELRAY BEACH, Fla., July 16, 2025 /PRNewswire/ -- The global Hemostats Market, valued at US$2.80 billion in 2024 stood at US$2.90 billion in 2025 and is projected to advance at a resilient CAGR of 6.4% from 2025 to 2030, culminating in a forecasted valuation of US$4.00 billion by the end of the period. The escalation in global accident rates has led to a surge in surgical procedures characterized by extended operating durations. A significant contributor to hemorrhage in surgical and trauma cases is the suboptimal application of conventional wound closure methods, including sutures, staples, and various hemostatic agents. This inadequacy underscores the growing demand for advanced blood loss management solutions, particularly effective hemostatic products, to optimize patient outcomes during surgical interventions. In this report, the hemostats market is segmented by type, formulation, application, end user, and region. Download PDF Brochure: Browse in-depth TOC on "Hemostats Market" 186 - Tables43 - Figures215 - Pages By type, the hemostats market is segmented into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats based on type. The oxidized regenerated cellulose-based hemostats segment accounted for the largest share of the hemostats market in 2024. ORC-based hemostatic agents have emerged as the preferred choice for surgical hemostasis due to their proven efficacy across a range of surgical specialties, including orthopedics, cardiovascular, and general surgery. These hemostats consistently demonstrate reliable hemostatic performance, making them indispensable in various intraoperative settings. Their versatility across diverse operating room conditions ensures that they are often the clinician's first choice for managing complex clinical scenarios. One of the substantial advantages of ORC-based hemostats is their bioabsorbable composition, which eliminates the need for surgical removal post-procedure and minimizes the risk of foreign-body reactions. Furthermore, certain ORC formulations possess inherent antimicrobial properties, providing an added defense against surgical site infections and thereby enhancing patient safety and post-operative outcomes. The increasing incidence of trauma cases and emergency surgeries has intensified the demand for prompt and effective hemostatic interventions within healthcare systems. In light of this trend, institutions are compelled to integrate reliable hemostatic agents into standard surgical protocols, driven by the dual objectives of improving surgical outcomes and reducing intraoperative blood loss. By formulation, the global hemostats market is differentiated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2024, the matrix & gel hemostats segment dominated the hemostats market. These formulations effectively balance versatility and efficacy, making them suitable for a wide range of surgical applications. Matrix and gel hemostats are particularly advantageous due to their straightforward application, even in challenging anatomical locations. Their ability to conform to irregular wound morphologies allows them to effectively address both profuse and oozing bleeding scenarios. Many formulations are compatible with laparoscopic techniques, facilitating the advancement of minimally invasive surgery. Moreover, certain matrix and gel combinations are integrated with active agents such as thrombin, which significantly enhances hemostatic performance and expedites clot formation. By applications, the hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. The reconstructive surgery segment is expected to witness the highest CAGR during the forecast period in the hemostats market. The observed increase in surgical interventions can be attributed to the rising prevalence of aesthetic and trauma-related procedures, including skin grafting, breast reconstruction, and craniofacial surgeries. The growing recognition and acceptance of aesthetic treatments, alongside improved access to surgical options, are further driving this demand. Additionally, the rising incidence of cancer-related surgeries, particularly post-mastectomy reconstructions, as well as trauma cases, are significant contributors to market growth. These procedures often involve delicate tissues with high vascularity, where meticulous hemostatic control is essential. This underscores the critical need for effective hemostatic agents in the operating room. Furthermore, advancements in reconstructive technologies are accelerating the adoption of specialized hemostatic products, enhancing outcomes in this evolving sector. By end user, the hemostats market can be divided by end user into three main categories: Hospitals, specialty clinics, and other end users. Hospitals represent the most substantial segment of the hemostats market, primarily due to the high volume of surgical procedures performed within their facilities. The intricate nature of these surgeries, along with the presence of specialized surgical departments, contributes significantly to the growing demand for effective bleeding control solutions. Complex and emergency cases, which frequently arise in hospitals, necessitate a reliable means of managing blood loss, thereby creating a continuous need for advanced hemostatic products. Additionally, hospitals often serve as the pioneers in adopting new surgical technologies and innovative products. This proactive approach is made possible by their enhanced funding capabilities and well-developed procurement processes, allowing them to stay at the forefront of medical advancements. The presence of highly skilled surgical specialists and comprehensive post-operative care units further amplifies the need for efficient hemostatic agents. These factors collectively ensure that hospitals remain a critical driver of demand in the hemostats market as they seek to improve patient outcomes and enhance surgical efficacy through cutting-edge bleeding control solutions. By geography, the market for hemostats has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the predominant portion of the hemostats market. North America is at the forefront of the hemostats market, propelled by its advanced healthcare infrastructure and the swift integration of cutting-edge medical technologies. This region exhibits a robust demand for both cosmetic and restorative procedures, significantly influenced by the escalating geriatric demographic and an uptick in surgical interventions. The increasing incidence of chronic diseases is projected to further amplify the volume of surgical procedures, thereby enhancing the requirement for effective hemostatic agents. The region's leadership in both innovation and market share is underscored by the concentration of numerous key players in the hemostats industry. Additionally, the high levels of disposable income and elevated standard of living in nations such as the US and Canada significantly contribute to the growing demand for premium medical treatments. Request Sample Pages : The prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey). Among other developments, these companies adopted strategies such as partnerships, collaborations, agreements, integrations, acquisitions, product launches, and expansions to strengthen their presence in the hemostats market. Johnson & Johnson Services, Inc. (US): In 2024, Johnson & Johnson Services, Inc. maintained its dominant position in the hemostats market, attributed to its expansive distribution networks across North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The company's extensive portfolio is particularly notable within the oxidized regenerated cellulose-based hemostats segment, with SURGICEL as its flagship brand for hemostatic agents. To bolster its market leadership, Johnson & Johnson leverages a strategic framework encompassing expansions, regulatory approvals, and innovative product launches. A significant move was made in May 2022, when Ethicon, a subsidiary under the Johnson & Johnson Medtech umbrella, acquired GATT Technologies B.V. This acquisition aims to enhance its biosurgery portfolio by incorporating synthetic polymer-based hemostatic technologies, exemplified by the development of advanced solutions such as the ETHIZIA Hemostatic Patch. Such strategic initiatives are pivotal in amplifying their market share and reinforcing Johnson & Johnson's entrenched position within the hemostats sector. Baxter (US) Baxter has emerged as a dominant force in the hemostats market as of 2024, securing a substantial market share largely due to its extensive and effective sales and distribution networks. With operations spanning over 100 countries, Baxter leverages both direct and indirect sales channels to optimize product reach and accessibility. The company's commitment to research and development is exemplary, facilitating the introduction of cutting-edge products that address evolving clinical needs. In addition to its organic growth strategies, such as new product launches, Baxter is also pursuing inorganic growth through strategic acquisitions, further solidifying its competitive position in the hemostats sector. Pfizer, Inc. (US) Pfizer, Inc. is a leading entity in the hemostats market as of 2024, operating within a robust global framework that spans approximately 125 countries, including regions such as North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company's established operations in the US provide a strategic platform for further penetration into emerging markets, thereby augmenting its geographical footprint. The rising adoption of foam-based hemostats is a key driver of significant revenue generation for Pfizer's hemostatic product offerings, reflecting a shift towards innovative solutions in the surgical and trauma care sectors. For more information, Inquire Now! Related Reports: Biosurgery Market Collagen & Gelatin Market Orthopedic Devices Market Biomaterials Market Adhesion Barrier Market Get access to the latest updates on Hemostats Companies and Hemostats Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
$6.71 Bn Absorbable Hemostats Market Opportunities and Strategies to 2034, Fueled by Aging Populations and Rise in Surgeries Despite Supply Chain Challenges
Absorbable Hemostats Market Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Absorbable Hemostats Market Opportunities and Strategies to 2034" report has been added to report describes and explains the absorbable hemostats market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global absorbable hemostats market reached a value of nearly $3.14 billion in 2024, having grown at a compound annual growth rate (CAGR) of 5.90% since 2019. The market is expected to grow from $3.14 billion in 2024 to $4.59 billion in 2029 at a rate of 7.87%. The market is then expected to grow at a CAGR of 7.91% from 2029 and reach $6.71 billion in in the historic period resulted from the rising surgical procedures, rising incidence of trauma and accidental injuries, increasing focus on blood loss management and rising healthcare expenditure. Factors that negatively affected growth in the historic period were high cost of hemostatic agents and high competition from non-absorbable forward, growing prevalence of chronic diseases, growing aging population and surge in orthopedic surgeries will drive the growth. Factor that could hinder the growth of the absorbable hemostats market in the future include supply chain disruptions and declining macroeconomic global absorbable hemostats market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 21.53% of the total market in 2023. Johnson & Johnson was the largest competitor with a 6.93% share of the market, followed by Baxter International Inc. with 6.90%, Becton, Dickinson and Company (C. R. Bard, Inc.) with 2.57%, Gelita AG with 1.57%, Samyang Holdings Corporation with 0.92%, Integra LifeSciences with 0.91%, B. Braun SE with 0.90%, Artivion Inc. (CryoLife Inc.) with 0.41%, Pfizer Inc. with 0.22% and Stryker Corporation with 0.20%.The absorbable hemostats market is segmented by type into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, gelatin-based hemostats, collagen-based hemostats and other types. The gelatin-based hemostats market was the largest segment of the absorbable hemostats market segmented by type, accounting for 36.45% or $1.14 billion of the total in 2024. Going forward, the oxidized regenerated cellulose-based hemostats segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by type, at a CAGR of 8.94% during absorbable hemostats market is segmented by application into neurosurgery, orthopedic surgery, general surgery, reconstructive surgery and other applications. The general surgery market was the largest segment of the absorbable hemostats market segmented by application, accounting for 31.37% or $986.42 million of the total in 2024. Going forward, the orthopedic surgery segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by application, at a CAGR of 9.11% during absorbable hemostats market is segmented by end-user into hospitals and clinics, ambulatory surgical centers and other end-users. The hospitals and clinics market was the largest segment of the absorbable hemostats market segmented by end-user, accounting for 66.31% or $2.08 billion of the total in 2024. Going forward, the ambulatory surgical centers segment is expected to be the fastest growing segment in the absorbable hemostats market segmented by end-user, at a CAGR of 9.91% during America was the largest region in the absorbable hemostats market, accounting for 39.64% or $1.24 billion of the total in 2024. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the absorbable hemostats market will be Asia-Pacific and Eastern Europe where growth will be at CAGRs of 8.58% and 8.51% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 8.41% and 8.18% top opportunities in the absorbable hemostats market segmented by type will arise in the gelatin-based hemostats segment, which will gain $477.75 million of global annual sales by 2029. The top opportunities in the absorbable hemostats market segmented by application will arise in the general surgery segment, which will gain $427.22 million of global annual sales by 2029. The top opportunities in the absorbable hemostats market segmented by end-user will arise in the hospitals and clinics segment, which will gain $888.35 million of global annual sales by 2029. The absorbable hemostats market size will gain the most in the USA at $479.43 strategies for the absorbable hemostats market include innovations in absorbable hemostats with focus on plant-based cellulose matrix solutions, investment in hemostatic product development, advancements with biocompatible modified polymer technology for minimally invasive procedures, driving surgical efficiency and safety with absorbable hemostatic powders and Advanced Sealing Patch For Effective Bleeding strategies in the absorbable hemostats market include focus on strengthening their business expertise through new launches and improving its portfolio through the launch of product take advantage of the opportunities, the analyst recommends the absorbable hemostats companies to focus on advancing biocompatible, sustainable hemostats, focus on leveraging private placement funding for innovation, focus on advancing biocompatible materials for minimally invasive procedures, focus on technological advancements in hemostatic powders, focus on advancing sealing patch technologies for rapid bleeding control, focus on developing bio adhesive hemostats with innovative materials, focus on thrombin-based hemostats to drive growth, expand in emerging markets, focus on expanding distribution channels for greater market reach, focus on developing competitive and flexible pricing strategies, focus on targeted marketing and educational campaigns, focus on collaborating with key opinion leaders and influencers, focus on orthopedic surgery to drive market growth and focus on hospitals and clinics to maximize Market Trends Innovations in Absorbable Hemostats With Focus on Plant-Based Cellulose Matrix Solutions Investment in Hemostatic Product Development Advancements With Biocompatible Modified Polymer Technology for Minimally Invasive Procedures Driving Surgical Efficiency and Safety With Absorbable Hemostatic Powders Advanced Sealing Patch for Effective Bleeding Control Hemostatic Solutions for Critical Surgical Situations Key Mergers and Acquisitions Advanced Medical Solutions Group PLC Acquired Peters Surgical Tube Investments of India Limited Acquired Lotus Surgicals Pvt Ltd. Warburg Pincus LLC Acquired Meril Life Sciences Ethicon Inc., Acquired GATT Technologies B.V. Baxter International Inc. Acquired CryoLife Inc Grifols S.a. Acquired Biotest AG Companies Featured Johnson & Johnson Baxter International Inc. Becton, Dickinson and Company (C. R. Bard, Inc.) Gelita AG Samyang Holdings Corporation Integra LifeSciences B. Braun SE Artivion Inc. (CryoLife Inc.) Pfizer Inc. Stryker Corporation Axio Biosolutions Futura Surgicare Pvt Ltd. Teleflex Inc. Medtronic Plc Z-Medica LLC CSL Behring Ethicon Meril Life Sciences Pvt Ltd. Teleflex Incorporated Scopio labs KITSS Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Absorbable Hemostats Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
